Monaschin and Ankaflavin- In Diabetic Nephropathy?

Soni, Navneet Omprakash

doi:10.20959/wjpps20179-9700

Cited by 1 publication

(1 citation statement)

References 11 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A new potential target in diabetic nephropathy has been identified. [43][44][45][46][47][48][49][50][51][52][53][54][55][56][57] The Wnt/β-catenin signaling pathway is involved in mesangial cell extracellular matrix (ECM) production (MCs). 58 Through the JNK/NF-B/NADPH oxidase/ROS pathway, high glucose promotes renal mesangial cell proliferation and fibronectin expression.…”

Section: Diabetic Nephropathymentioning

confidence: 99%

Berbamine application beyond cancer

Soni¹

2021

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

The main purpose of this review was to ascertain the clinical application and future non oncological uses of Berbaminebamine (BERBAMINE). Berbaminebamine, as a STAT3 (signal transducer and activator of transcription) inhibitor, antioxidant, anti-inflammatory and modulator of many signalling pathways, should be investigated in autoimmune diseases. Berbaminebamine has been found to have pharmacological activity in the following cancers: breast cancer, lung cancer, prostate cancer, pancreatic cancer, ovarian cancer, glioblastoma, colon cancer, bladder cancer, chronic myeloid leukemia, hepatocellular carcinoma, triple negative breast cancer and osteosarcoma. Ischemic reperfusion injury, melanoma, COVID-19 and allergy diseases are among the conditions for which it is beneficial. It may aid in the treatment of obesity, metabolic syndrome, inflammatory syndrome, sepsis, COVID-19, dengue fever, Nipah virus infection, influenza, solid tumors, lymphoma, cancer, hematological malignancies, skin inflammatory disorder and atopic dermatitis. BERBAMINE can be used as versatile molecule in alcoholic liver disease, diabetic nephropathy and antiviral, anti-inflammatory.

show abstract